Abstract
Solid organ transplant (SOT) recipients are at enhanced risk of adverse outcomes following infectious challenges due to immunosuppressive treatment and additional comorbidities. Unfortunately, SOT recipients are also poor responders to the key medical intervention to preventing infection: vaccines. Here we performed a systems vaccinology study on a cohort of 59 kidney transplant recipients and 31 lung transplant recipients who received the mRNA Pfizer-BioNTech COVID-19 vaccine. Analyzing the immunological status of the patients prior to vaccination, we were able to identify multiple immunological associates of relatively improved vaccine responses following two or three doses of mRNA-based SARS-CoV-2 vaccine. These immunological associates predicted, with 95.0% and 93.3% accuracy, vaccine response after the second and third dose, respectively. Comparison of the immunological associates with vaccine response in SOT recipients revealed two distinct immune configurations: a non-classical configuration, distinct from the immune state of healthy subjects, associated with responses to two doses of mRNA vaccine and that could be mediated partly by the presence of double negative B cell subsets which are more prominently represented in responsive SOT recipients, and a “normalized” configuration, closer to the immune state of healthy subjects, associated with potent antibody responses to three doses of mRNA vaccine. These results suggest that immunosuppression in SOT recipients can result in distinct immune states associated with different trade-offs in vaccine responsiveness. Immune phenotyping of SOT recipients for immune constellation may be an effective approach for identifying patients most at risk of poor vaccine responses and susceptibility to vaccine-preventable diseases.
One-sentence summary SOT recipients showed distinct immune states at baseline associated with different profiles of vaccine-associated immune response.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was co-funded by the Belgian Federal Government through Sciensano and by the Fonds de la Recherche Scientifique (F.R.S.-FNRS) Belgium. This work has received funding from the KU Leuven C1 program and the European Union Horizon 2020 research and innovation programme under grant agreement No 874707 (EXIMIOUS) (to SHB and AL) and the Biotechnology and Biological Sciences Research Council (BBSRC) through Institute Strategic Program Grant funding BBS/E/B/000C0427 and BBS/E/B/000C0428 and the KU Leuven BOFZAP start-up grant (to SHB). This study was supported by the European Regional Development Fund (ERDF) of the Walloon Region (Wallonia-Biomed portfolio, 411132-957270).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee of Hopital Erasme, Brussels, Belgium (references P2021/182 and A2021/156 for lung transplant recipients; P2020/284 and A2021/131 for kidney transplant recipients) and the Belgian Federal Agency for Medicines and Health Products (FAMHP, EudraCT 2021-004992-16 for lung transplant recipients; EudraCT 2021-000-412-28 for kidney transplant recipients) approved the monocentric prospective phase IV investigator-initiated study of the immunogenicity of the BNT161b2 vaccine (Pfizer-BioNTech). The ethics committee of CHU Saint-Pierre approved a 6-month study on the carriage and seroprevalence of SARS-CoV-2 in health-care workers (CE/20-04-17).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced are available online at http://flowrepository.org/id/FR-FCM-Z662
